Astellas bought IVERIC for $40.00 per share in cash, for a total equity value of approximately $5.9 billion.
(Reporting by Baranjot Kaur in Bengaluru; Editing by Kim Coghill)
(Reuters) - Japan's Astellas Pharma said on Monday it had fully acquired drugmaker IVERIC Bio Inc, through Berry Merger Sub, Inc, a wholly-owned subsidiary of Astellas US Holding, Inc.
Astellas bought IVERIC for $40.00 per share in cash, for a total equity value of approximately $5.9 billion.
(Reporting by Baranjot Kaur in Bengaluru; Editing by Kim Coghill)
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
1,510 JPY | +0.50% | -4.25% | 17.12B | ||
39.95 USD | +0.38% | +1.09% | 5.51B | ||
2,700 PTS | -1.70% | -2.96% | - | ||